182 related articles for article (PubMed ID: 32789758)
1. Identifying optimal magnesium replenishment points based on risk of severe hypomagnesemia in colorectal cancer patients treated with cetuximab or panitumumab.
Kimura M; Usami E; Teramachi H; Yoshimura T
Cancer Chemother Pharmacol; 2020 Sep; 86(3):383-391. PubMed ID: 32789758
[TBL] [Abstract][Full Text] [Related]
2. Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Schulz C; Heinemann V; Heinrich K; Haas M; Holch JW; Fraccaroli A; Held S; von Einem JC; Modest DP; Fischer von Weikersthal L; Kullmann F; Moehler M; Scheithauer W; Jung A; Stintzing S
Anticancer Drugs; 2020 Sep; 31(8):856-865. PubMed ID: 32639280
[TBL] [Abstract][Full Text] [Related]
3. Effects of Type of Antibody to EGFR and Hypomagnesemia on Overall Survival in First-line Treatment of Patients With Unresectable Advanced/Recurrent Colorectal Cancer.
Kimura M; Usami E; Yoshimura T
Anticancer Res; 2020 Dec; 40(12):7135-7140. PubMed ID: 33288613
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of Factors Influencing the Development of Hypomagnesemia in Patients Receiving Cetuximab Therapy for Head and Neck Cancer].
Inose R; Takahashi K; Nishikawa T; Nagayama K
Yakugaku Zasshi; 2015; 135(12):1403-7. PubMed ID: 26632157
[TBL] [Abstract][Full Text] [Related]
5. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
[TBL] [Abstract][Full Text] [Related]
6. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.
Vickers MM; Karapetis CS; Tu D; O'Callaghan CJ; Price TJ; Tebbutt NC; Van Hazel G; Shapiro JD; Pavlakis N; Gibbs P; Blondal J; Lee U; Meharchand JM; Burkes RL; Rubin SH; Simes J; Zalcberg JR; Moore MJ; Zhu L; Jonker DJ
Ann Oncol; 2013 Apr; 24(4):953-60. PubMed ID: 23144444
[TBL] [Abstract][Full Text] [Related]
7. Importance of magnesium sulfate supplementation in the prevention of hypomagnesemia and hypocalcemia during chemoradiation in head and neck cancer.
Grašič Kuhar C; Strojan P; Zadnik V; Zakotnik B
J Trace Elem Med Biol; 2018 Dec; 50():327-331. PubMed ID: 30262299
[TBL] [Abstract][Full Text] [Related]
8. [The Incidence of Cisplatin-induced Hypomagnesemia in Cervical Cancer Patients Receiving Cisplatin Alone].
Yamamoto Y; Watanabe K; Matsushita H; Tsukiyama I; Matsuura K; Wakatsuki A
Yakugaku Zasshi; 2017; 137(1):79-82. PubMed ID: 28049899
[TBL] [Abstract][Full Text] [Related]
9. Hypomagnesemia and Survival in Patients with Ovarian Cancer Who Received Chemotherapy with Carboplatin.
Liu W; Qdaisat A; Soliman PT; Ramondetta L; Lopez G; Narayanan S; Zhou S; Cohen L; Bruera E; Yeung SJ
Oncologist; 2019 Jun; 24(6):e312-e317. PubMed ID: 30940743
[TBL] [Abstract][Full Text] [Related]
10. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
Ouwerkerk J; Boers-Doets C
Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
[TBL] [Abstract][Full Text] [Related]
11. A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Liu T; Jiang S; Teng X; Zhong L; Liu M; Jin Y; Dong M
Immunopharmacol Immunotoxicol; 2023 Feb; 45(1):1-9. PubMed ID: 35950851
[TBL] [Abstract][Full Text] [Related]
12. Influence of oral magnesium-containing supplement and antacid administration on hypomagnesemia induced by panitumumab.
Sato J; Ishikawa H; Tanaka R; Sino M
Cancer Chemother Pharmacol; 2019 Apr; 83(4):673-679. PubMed ID: 30661095
[TBL] [Abstract][Full Text] [Related]
13. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
[TBL] [Abstract][Full Text] [Related]
14. Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis.
Hsieh MC; Wu CF; Chen CW; Shi CS; Huang WS; Kuan FC
Sci Rep; 2018 Feb; 8(1):2047. PubMed ID: 29391418
[TBL] [Abstract][Full Text] [Related]
15. Hypomagnesemia During Teriparatide Treatment in Osteoporosis: Incidence and Determinants.
Bégin MJ; Ste-Marie LG; Coupal L; Ethier J; Räkel A
J Bone Miner Res; 2018 Aug; 33(8):1444-1449. PubMed ID: 29637622
[TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
[TBL] [Abstract][Full Text] [Related]
17. Durable complete remission following anti-EGFR antibodies in recurrent metastatic colorectal cancer.
Boudrias-Dalle E; Cloutier M; Harvey M; Leblanc G; Besner-Morin O; Adam JP
J Oncol Pharm Pract; 2019 Jan; 25(1):239-243. PubMed ID: 28950807
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab-induced hypomagnesemia in patients with colorectal cancer.
Fakih MG; Wilding G; Lombardo J
Clin Colorectal Cancer; 2006 Jul; 6(2):152-6. PubMed ID: 16945172
[TBL] [Abstract][Full Text] [Related]
20. Isolated hypomagnesemia in a patient treated with capecitabine.
Rajapakse S; Rodrigo C; Rajapakse AC
J Oncol Pharm Pract; 2013 Sep; 19(3):254-6. PubMed ID: 22948887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
